Compare GGT & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGT | RANI |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 126.8M |
| IPO Year | N/A | 2021 |
| Metric | GGT | RANI |
|---|---|---|
| Price | $4.15 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 331.6K | ★ 804.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | ★ 21.05 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $1,028,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $0.39 |
| 52 Week High | $4.94 | $3.87 |
| Indicator | GGT | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 55.52 |
| Support Level | $4.13 | $1.31 |
| Resistance Level | $4.29 | $1.42 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 58.85 | 83.33 |
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.